Evidence map›Paper›PMID 18809717›Full record

ArticleThe Journal of experimental medicine2008

Chemerin reveals its chimeric nature.

Teizo Yoshimura, Joost J Oppenheim

Open access · greenAbstract readComment
In one paragraph

Article in The Journal of experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Chemerin/ChemerinR1 axis and inflammation-related diseases.Frontiers in molecular biosciences · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. The Role of Peptides in Asthma-Obesity Phenotype.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Metabolic aspects of hepatitis C virus.World journal of gastroenterology · 2022
    Review
  18. Article
  19. Article
  20. Metabolic complications of hepatitis C virus infection.World journal of gastroenterology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Teizo YoshimuraLaboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA. yoshimut@mail.nih.gov
Joost J Oppenheim
Frederick National Laboratory for Cancer Research · US

Funding

Studies of Receptor Interactions and Effects of AlarminsZIABC009369 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OPPENHEIM, JOOST J · 2009 to 2022
$16.5M
Studies of Chemokine-Receptor Interactions with Chemokines and alarminsZ01BC009369 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OPPENHEIM, JOOST J · 1996 to 2008
$1.8M
6 · The paper itself

Abstract

Chemerin is a proinflammatory plasma protein that binds to the GPCR ChemR23/CMKLR1 on macrophages and plasmacytoid dendritic cells, and promotes chemotaxis. An orphan GPCR, CCRL2, has now been identified as an additional receptor for chemerin, providing a unique mechanism by which chemerin enhances inflammation. Furthermore, because recent data shows that chemerin-derived peptides possess antiinflammatory properties, chemerin may be involved in both the initiation and resolution of inflammation.

Indexed as

AnimalsChemokinesDendritic CellsHumansInflammationIntercellular Signaling Peptides and ProteinsMacrophagesModels, MolecularPeptidesProtein PrecursorsReceptors, ChemokineChemokinesCMKLR1 protein, humanIntercellular Signaling Peptides and ProteinsPeptidesProtein PrecursorsRARRES2 protein, humanReceptors, Chemokine

Identifiers

PMID18809717
PMCPMC2556799
OpenAlexW2143695755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.